Abstract
Mucolytic and related agents have been in use since prehistoric times. Although widely prescribed and used extensively in over-the-counter preparations, their efficacy and mechanisms of action remain in doubt. These agents belong to several distinct chemical classes. Mucolytic agents such as N-acetyl-cysteine are thiols with a free-sulfhydryl group. They are assumed to break disulfide bonds between gelforming mucins and thus reduce mucus viscosity. Mucokinetic agents are thiols with a blocked sulfhydryl group. Expectorants such as guaifenesin increase mucus secretion. They may act as irritants to gastric vagal receptors, and recruit efferent parasympathetic reflexes that cause glandular exocytosis of a less viscous mucus mixture. Cough may be provoked. This combination may flush tenacious, congealed mucopurulent material from obstructed small airways and lead to a temporary improvement in dyspnea or the work of breathing. The roles of anticholinergic agents, DNase, and other drugs are also discussed with regard to their roles in reducing mucus production in rhinitis and other airway diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Reid L: Secretory Cells. Fed Proc 1977, 36:2703–2707.
Verma M, Davidson EA: Mucin gene: structure, expression, and regulation. Glycoconjugate J 1994, 11:172–179.
Brandtzaeg C: Immune functions of human nasal mucosa and tonsils in health and disease. In Immunology of the Lung and Upper Respiratory Tract. Edited by Bienenstock J. New York: McGraw-Hill; 1984:28–95.
Braga PC, Allegra L (eds): Drugs in Bronchial Mucology. New York: Raven Press; 1989:1–368. Although an older reference, this remains the best review of all pharmacologic approaches used to address mucus hypersecretion and expectoration.
Ziment I: Respiratory Pharmacology and Therapeutics. Philadelphia: WB Saunders; 1988.
Rogers DF, Lethem MI (eds): Airway Mucus: Basic Mechanisms and Clinical Perspectives. Basel: Birkhauser; 1997:1–388.
Hsu HY, Peacher WG, Chen H: History of Chinese medical science. Bull Orient Arts Inst 1977, 2:6.
Majno G: The Healing Hand, Man, and Wound in the Ancient World. Cambridge: Harvard University Press; 1975.
Chung KF, Dent G, McCusker M, et al.: Effect of a ginkgolide mixture, BN 52063, in antagonizing skin and platelet response to platelet activating factor. Lancet 1987, 8527:248–251.
Richardson P: Oral N-acetyl-cystine: How does it act? Eur J Resp Dis 1987, 70:71–72.
Stephan U, Bowing B, Goering U, et al.: Acetylcysteine in chronic treatment of cystic fibrosis. Eur J Respir Dis 1980, 61(Suppl 111):127–131.
Boman G, Backer U, Larsson S, et al.: Oral acetyl cystine reduces exacerbation rate in chronic bronchitis, report of a trial organized by the Swedish Society for Pulmonary Disease. Eur J Resp Dis 1983, 64:405–415.
Multicenter Study Group: Long term oral acetyl cystine in chronic bronchitis, a double blind controlled study. Eur J Respir Dis 1980, 61(Suppl 111):93–108.
Rochat T, Lacroix JS, Jornot L: N-acetylcysteine inhibits Na+ absorption across human nasal epithelial cells. J Cell Physiol 2004, 201:106–116.
Steen SN, Ziment I, Freeman D, Thomas JS: Evaluation a new mucolytic drug. Clin Pharmacol Ther 1974, 16:58–62.
Boonyapiwat B, Forbes B, Steventon GB: Phenylalanine hydroxylase: possible involvement in the S-oxidation of Scarboxymethyl-l-cysteine. Anal Biochem 2004, 335:91–97.
Miskovits G, Szule P, Appel J, Meszaros M: La mucoregolation element important dans le traitement du syndrome bronchitique. Med Klin 1984, 79:88–92.
Majima Y, Takeuchi K, Sakakura Y: Effects of myringotomy and orally administered drugs on viscosity and elasticity of middle ear effusions from children with otitis media with effusion. Acta Otolaryngol Suppl (Stockh) 1990, 471:66–72.
Schroeder K, Fahey T: Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2004, 4:CD001831. A recent review and metaanalyses of commonly used therapies.
Tsujimoto T, Takano M, Tsuruzono T, et al.: Mediastinal pancreatic pseudocyst caused by obstruction of the pancreatic duct was eliminated by bromhexine hydrochloride. Intern Med 2004, 43:1034–1038.
Stetinova V, Herout V, Kvetina J: In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med 2004, 4:152–158.
Petty TL: The national mucolytic study: results of a randomized, double blind, placebo controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990, 98:1309–1310.
Ferrari S, Donati C, Legnani W: Studio clinico controllato dell’attivata terapeutica del domiodolo. Riv Patol Clin 1981, 36:139–154.
Juergens UR, Dethlefsen U, Steinkamp G, et al.: Anti-inflammatory activity of 1,8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. Respir Med 2003, 97:250–256. The recent increase in interest in COPD has spurred properly designed studies to investigate specific drugs. Here, the active ingredient in eucalyptus preparations was shown to have a beneficial effect.
Meltzer EO: Intranasal anticholinergic therapy of rhinorrhea. J Allergy Clin Immunol 1992, 90:1055–1064.
Gross NJ: Anticholinergic agents. In Pulmonary and Critical Care Pharmacology and Therapeutics. Edited by Leff AR. New York: McGraw-Hill; 1996:535–552.
Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004, 84:731–765.
Gal TJ, Suratt PM, Lu J: Glycopyrrolate and atropine inhalation: comparative effects on normal airway function. Am Rev Respir Dis 1984, 129:871–873.
Bronsky EA, Druce H, Findlay SR, et al.: A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol 1995, 95:1117–1122.
Diamond L, Dockhorn RJ, Grossman J, et al.: A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol 1995, 95:1139–1146.
Saketkhoo K, Januskiewicz A, Sackner MA: Effects of drinking hot water, cold water, and chicken soup on nasal mucus, velocity and nasal airflow resistance. Chest 1978, 74:408–410.
Jones AP, Wallis CE: Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003, 3:CD001127.
Vasconcellos CA, Allen PG, Wohl ME, Stossel TP: Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994, 263:969–971.
Brandt T, Breitenstein S, Hardt HV, Tümmler B: DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax 1995, 50:880–882.
Claman DM, Bousher HA, Lui J, et al.: Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol 1994, 94:861–869.
Goswami SK, Kivity S, Marom Z: Erythromycin inhibits respiratory glycoconjugate secretion from human airway in vivo. Am Rev Respir Dis 1990, 141:72–78.
Tamaoki J, Isono K, Sakai N, et al.: Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992, 5:234–238.
Gotfried MH: Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004, 125(2 Suppl):52S-60S. Macrolides have had many effects in vitro and apparently in vivo. The nonantibiotic properties of specific macrolides and the general class are discussed as well as the place of these antibiotics for each condition.
Iino Y, Okura S, Shiga J, et al.: Histopathological studies on paranasal mucosa from patients treated with erythromycin. J Otolaryngol Jpn 1994, 97:1070–1078.
Anonymous: Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998. Drugs R D 2003, 4:359-362.
Poole PJ, Black PN: Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Crit Care Med 2003, 2:367–370. This recent review suggests a possible role of mucolytic and other agents for reducing exacerbation rates in COPD.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yuta, A., Baraniuk, J.N. Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep 5, 243–251 (2005). https://doi.org/10.1007/s11882-005-0044-6
Issue Date:
DOI: https://doi.org/10.1007/s11882-005-0044-6